K-Ras(G12C) inhibitor 9   Click here for help

GtoPdb Ligand ID: 8022

Compound class: Synthetic organic
Comment: This compound is a selective allosteric inhibitor of oncogenic KRASG12C [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 96.12
Molecular weight 513
XLogP 2.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COc1cc(Cl)c(cc1NCC(=O)N1CCC(CC1)NS(=O)(=O)C=C)I
Isomeric SMILES COc1cc(Cl)c(cc1NCC(=O)N1CCC(CC1)NS(=O)(=O)C=C)I
InChI InChI=1S/C16H21ClIN3O4S/c1-3-26(23,24)20-11-4-6-21(7-5-11)16(22)10-19-14-9-13(18)12(17)8-15(14)25-2/h3,8-9,11,19-20H,1,4-7,10H2,2H3
InChI Key ZGUSBCDCZNBNQT-UHFFFAOYSA-N
No information available.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
This compound binds irreversibly to the mutant cysteine residue in oncogenic KRASG12C so has no effect on wildtype protein. This mechanism of action surmounts the pharmacological problem of attempting to competitively inhibit GTP/GDP binding which occurs with picomolar affinities at RAS proteins. The effect of ligand binding shifts the mutant RAS to favour GDP binding (ie the inactive state) and impairs interactions with effectors such as Raf and regulatory proteins such as the GEF, SOS1.